ArticleCureus2020
Comparison of Efficacy of Cannabinoids versus Commercial Oral Care Products in Reducing Bacterial Content from Dental Plaque: A Preliminary Observation.
Article in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05498012 (Cannabidiol Effects on Chronic Periodontitis), which is not on this map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cannabidiol Effects on Chronic Periodontitis: Monocentric, Randomized, Interventional and Placebo-controlled Study
Who cites it
37 citing papers in PubMed, 52 citations in OpenAlex.
- Therapeutic Potential of Cannabidiol in Dysbiosis-Related Oral Biofilm Diseases: Antibiofilm, Antivirulence and Host Response Evidence.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Effect of a cannabidiol-based mouthwash on dental enamel properties and biofilm control: an In situ study.Clinical oral investigations · 2026Article
- Evaluation of the antimicrobial effect of cannabidiol (CBD) in a multispecies subgingival biofilm model.Journal of oral microbiology · 2026Article
- Potential Antimicrobial Use of Cannabidiol in Dentistry: A Scoping Review.Dentistry journal · 2025Review
- Cannabichromene, a key non-psychotropic phytocannabinoid in treatment of major depressive disorder: in silico and in vivo explorations.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Investigating the Antimicrobial Efficacy of Cannabinoids and Their Derivatives AgainstBiology · 2025Article
- The Incorporation of CBD into Biodegradable DL-Lactide/Glycolide Copolymers Creates a Persistent Antibacterial Environment: An In Vitro Study onPharmaceutics · 2025Article
- Antimicrobial Denture Material Synthesized from Poly(methyl methacrylate) Enriched with Cannabidiol Isolates.Molecules (Basel, Switzerland) · 2025Article
- Antimicrobial Potential of Cannabinoids: A Scoping Review of the Past 5 Years.Microorganisms · 2025Review
- The Potential of Cannabichromene (CBC) as a Therapeutic Agent.The Journal of pharmacology and experimental therapeutics · 2024Review
- The Role of Different Types of Cannabinoids in Periodontal Disease: An Integrative Review.Pharmaceutics · 2024Review
- Combinations of Cannabinoids with Silver Salts or Silver Nanoparticles for Synergistic Antibiotic Effects against Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Evaluating the Metabolomic Profile and Anti-Pathogenic Properties ofMetabolites · 2024Review
- A narrative review of the therapeutic and remedial prospects of cannabidiol with emphasis on neurological and neuropsychiatric disorders.Journal of cannabis research · 2024Review
- Article
- Cannabidiol for Oral Health: A New Promising Therapeutical Tool in Dentistry.International journal of molecular sciences · 2023Review
- Improved Anti-Biofilm Effect against the Oral CariogenicBiomedicines · 2023Article
- Anti-Bacterial Effect of Cannabidiol against the CariogenicInternational journal of molecular sciences · 2022Article
- Cannabidiol in Dentistry: A Scoping Review.Dentistry journal · 2022Article
- Antimicrobial and Cytotoxic Effects of Cannabinoids: An Updated Review with Future Perspectives and Current Challenges.Pharmaceuticals (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Dental plaque is a complex biofilm that gets formed on the teeth and acts as a reservoir of different microbes. It is the root cause for the occurrence of several dental problems and diseases, including cavities, bad breath, bleeding gums, tooth decay, and tooth loss. Therefore, it should be regularly removed using suitable oral care aids. Objectives The present study compared the efficacy of oral care products and cannabinoids in reducing the bacterial content of dental plaques. Methods Sixty adults aged 18 to 45 years were categorized into six groups based on the Dutch periodontal screening index. Dental plaques of the adults were collected using paro-toothpick sticks and spread on two Petri dishes, each with four divisions. On Petri dish-A, cannabidiol (CBD), cannabichromene (CBC), cannabinol (CBN), and cannabigerol (CBG) were used, and on Petri dish-B, cannabigerolic acid (CBGA), Oral B, Colgate, and Cannabite F (a toothpaste formulation of pomegranate and algae) were used. The Petri dishes were sealed and incubated, followed by counting the number of colonies. Results By evaluating the colony count of the dental bacteria isolated from six groups, it was found that cannabinoids were more effective in reducing the bacterial colony count in dental plaques as compared to the well-established synthetic oral care products such as Oral B and Colgate. Conclusion Cannabinoids have the potential to be used as an effective antibacterial agent against dental plaque-associated bacteria. Moreover, it provides a safer alternative for synthetic antibiotics to reduce the development of drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.